



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G02B 1/04, C08F 20/30, 20/36, A61L 27/00	A1	(11) International Publication Number: WO 99/53348 (43) International Publication Date: 21 October 1999 (21.10.99)
(21) International Application Number: PCT/US99/07362 (22) International Filing Date: 1 April 1999 (01.04.99) (30) Priority Data: 60/081,874 15 April 1998 (15.04.98) US (71) Applicant: ALCON LABORATORIES, INC. [US/US]; R & D Counsel Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US). (72) Inventor: LEBOEUF, Albert, R.; 7861 Mahonia, Fort Worth, TX 76133 (US). (74) Agents: RYAN, Patrick, M. et al.; R & D Counsel Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		(81) Designated States: AU, BR, CA, CN, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HIGH REFRACTIVE INDEX OPHTHALMIC DEVICE MATERIALS PREPARED USING A POST-POLYMERIZATION CROSS-LINKING METHOD (57) Abstract Acrylic, high refractive index ophthalmic device materials comprising an aryl acrylic monomer, a first stage polymerization initiator and a second stage cross-linking agent are prepared in a two-stage method. The monomers used to form the ophthalmic device materials do not contain cross-linking agents having more than one unsaturated bond. In the first stage of the method, the materials are polymerized. In the second stage, the materials are cross-linked by exposure to heat.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HIGH REFRACTIVE INDEX OPHTHALMIC DEVICE MATERIALS PREPARED USING A POST-POLYMERIZATION CROSS-LINKING METHOD

FIELD OF THE INVENTION

5 This invention relates to a method of preparing high refractive index ophthalmic device materials. In particular, the present invention relates to a two-stage method in which ophthalmic device materials are first polymerized and then cross-linked.

BACKGROUND OF THE INVENTION

10 The two most common types of polymerization initiators for ophthalmic device materials are thermal initiators and photoinitiators. Typical thermal initiators, including free radical initiators such as peroxides, initiate polymerization as temperature is increased. In some cases, two or three temperature tiers are involved such that curing involves a schedule of temperature/time combinations. Thermal initiation generally requires holding the monomer composition at elevated temperatures for lengthy periods of time. Total cure times of twenty-four hours are not unusual. See, for example, U.S. Patent No. 5,290,892.

25 Photoinitiators generally offer the advantage of relatively short cure times and, unlike thermal initiators, can be used at ambient conditions, eliminating the need for high-temperature equipment or special ovens. Photoinitiators are activated by radiation of one or more specified wavelengths, rather than heat. Photoinitiation of ophthalmic lens materials is known. See, for example, U.S. Patent No. 5,290,892.

30 The most common types of photoinitiators known or used for curing ophthalmic lens polymers are probably UV-sensitive photoinitiators. UV-sensitive photoinitiators are, however, generally not suitable for use with lens

materials that contain a UV-absorbing chromophore. UV-absorbing chromophores present in an ophthalmic lens composition can interfere with the ability of UV-sensitive photoinitiators to efficiently cure the composition. Today, UV-absorbing chromophores are frequently incorporated in ophthalmic lens materials in order to reduce or block UV light from reaching the retina. Although methods are known for temporarily "blocking" UV absorbing chromophores during processing, thereby preventing interference with a UV-initiator, these methods require that the UV-absorber be "un-blocked" after the composition is cured. The UV chromophore can be "un-blocked" by either chemical or thermal means. "Un-blocking" is generally complicated and can add 4 - 6 hours to processing times, offsetting some or all of the time advantages offered by photoinitiators.

In addition to UV-sensitive photoinitiators, visible-light initiators are also known. For example, U.S. Patent No. 5,224,957 discloses photopolymerizable compositions useful in forming an intraocular lens in situ. The compositions are delivered into the natural lens capsule or a thin plastic shell substitute and then polymerized. The reference compositions contain 90 - 99.99% by weight of at least one polyfunctional acrylic and/or methacrylic acid ester. Suitable acid esters include bisphenol A or bis(hydroxy)polyalkoxy bisphenol A derivatives lengthened with ethylene oxide or propylene oxide. The compositions of the '957 patent are cured using photoinitiators which absorb light in the range 400 - 500 nm. Suitable initiators include alpha-diketones, in particular camphorquinone, benzil and phenanthrene quinone, and mono and bisacylphosphine oxides.

International Patent Application Publication No. WO 96/28762 also discloses photocurable compositions comprising acrylic components. The compositions contain specified amounts of di(meth)acrylates, poly(meth)acrylates, urethane(meth)acrylates, and oligomeric di(meth)acrylates based on bisphenol A or bisphenol F. The photoinitiator may be "any photoinitiator which forms free radicals when irradiated suitably." Suitable

classes include benzoin ethers; acetophenones; benzil; anthraquinones; benzoylphosphine oxides (e.g., 2,4,6-trimethylbenzoyldiphenylphosphine oxide); benzophenones. Photoinitiators particularly suitable for use with argon ion lasers include 2,4,6- trimethylbenzoyldiphenylphosphine oxide.

5

Some ophthalmic devices are obtained by a monomer cast polymerization method. In such a method, the monomer solution is cast directly into a mold of desired shape and then polymerized or cured, followed by any machining or polishing, etc. See, for example, U.S. Patent Nos. 4,921,205 and 5,290,892.

10

In other cases, ophthalmic device materials are formed by first preparing a "prepolymer" or partially cured material, followed by further curing. See, for example, U.S. Patent No. 5,374,663 describing a prepolymer process for producing a U.V. absorber-containing intraocular lens material in which a monomer solution comprising a lens-forming monomer, an U.V. absorber and a polymerization initiator is introduced into a reactor and heated for a length of time and at a temperature sufficient to obtain a prepolymer of high viscosity. Thereafter, the prepolymer is filtered, cast into a cell or mold and further heated for a time at a temperature sufficient to obtain a transparent lens material.

20

According to the '663 patent, the prepolymer process has the advantage that the prepolymer scarcely leaks out of the cell or mold because of its high viscosity, and that the degree of shrinkage in the step of obtaining a lens material from the prepolymer is small. On the other hand, the prepolymer process has some problems as well, including (i) the control of the polymerization degree and viscosity of the prepolymer obtained in the first polymerization step, and (ii) when a cross-linking monomer is contained in the material, an insoluble polymer is formed in the prepolymer step, making any filtration treatment difficult or impossible, and the polymer produced after the further curing step becomes "non-uniform."

30

SUMMARY OF THE INVENTION

The present invention relates to a method for preparing acrylic, high refractive index ophthalmic device materials. The ophthalmic device materials
5 comprise at least one aryl acrylic hydrophobic monomer, a first stage polymerization initiator selected from the group consisting of low-temperature thermal initiators and photoinitiators, and a second stage cross-linking agent selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds, and dicumyl peroxide. The monomers used to form the
10 ophthalmic device materials do not contain any ingredient having more than one unsaturated site, as such ingredients will cause premature cross-linking.

According to the present invention, the ophthalmic device material is prepared using a two-stage process. In the first stage, the material is
15 polymerized such that the second stage cross-linking agent is not activated. In the second stage, the material is cross-linked by activating the cross-linking agent. The two-stage process of the present invention can provide enhanced control of material shrinkage and stress problems associated with cast molding operations compared to single stage curing processes.

20

DETAILED DESCRIPTION OF THE INVENTION

As used herein, "high refractive index" means a refractive index of about 1.50 or greater when measured at room temperature using an Abbe'
25 refractometer at 589 nm (Na light source).


As used herein, "low-temperature thermal initiator" means a thermal initiator that has an activation temperature lower than the activation temperature of the chosen second stage cross-linking agent.

30

According to the present invention, acrylic, high refractive index ophthalmic device materials are prepared in two stages. In the first stage, the

device material is polymerized. In the second stage, the device material is cross-linked.

The ophthalmic device materials of the present invention comprise at least one compound of Formula I below.



wherein: X is H or CH₃;

m is 0-10;

Y is nothing, O, S, or NR wherein R is H, CH₃, C_nH_{2n+1} (n=1-10) iso OC₃H₇, C₆H₅, or CH₂C₆H₅;

Ar is any aromatic ring which can be unsubstituted or substituted with CH₃, C₂H₅, n-C₃H₇, iso-C₃H₇, OCH₃, C₆H₁₁, Cl, Br, C₆H₅, or CH₂C₆H₅.

Monomers of Formula I are known and include, but are not limited to: 2-phenoxyethyl acrylate; 2-phenylethylthio acrylate; 2-phenylethylamino acrylate; phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate; 3-phenylpropyl acrylate; 3-phenoxypropyl acrylate; 4-phenylbutyl acrylate; 4-phenoxybutyl acrylate; 4-methylphenyl acrylate; 4-methylbenzyl acrylate; 2-2-methylphenylethyl acrylate; 2-3-methylphenylethyl acrylate; 2-4-methylphenylethyl acrylate; and their corresponding methacrylate compounds. These acrylic/methacrylic monomers and others are disclosed in U.S. Patent No. 5,290,892, the entire contents of which are hereby incorporated by reference.

Preferred monomers of Formula (I) are those where m is 2-4; Y is nothing or O; and Ar is phenyl. Most preferred are 2-phenylethyl acrylate, 2-phenoxyethyl acrylate, 3-phenylpropyl acrylate, 3-phenoxypropyl acrylate, 4-phenylbutyl acrylate, and 4-phenoxybutyl acrylate, and their corresponding methacrylate compounds.

The ophthalmic device materials of the present invention preferably contain at least two monomers of Formula I, wherein at least one is a methacrylate monomer ($X = \text{CH}_3$) and at least one is an acrylate monomer ($X = \text{H}$). The exact amount of monomer of Formula I present in the acrylic, high refractive index ophthalmic device materials of the present invention will vary depending upon the identity of the monomer(s) of Formula I, the identity of any other device-forming monomer(s) present in the materials, and the desired mechanical properties. For example, foldable intraocular lenses are preferably made from polymers having a glass transition temperature no greater than normal room temperature, e.g., about 20 – 25 °C, in order that the lenses can be rolled or folded conveniently at room temperature. Materials having a glass transition temperature of about 15 °C or less are even more preferred for foldable intraocular lens applications. Glass transition temperature is determined at room temperature using a differential scanning calorimeter at a heating rate of 10°C/min.

Additionally, materials exhibiting an elongation of at least 150% when measured at room temperature using an Instron tensile tester at a cross-head speed of 50 cm/min) are preferred for use in foldable intraocular lenses because such lenses must exhibit sufficient strength to allow them to be folded without fracturing. For foldable intraocular lens applications, polymers having an elongation of at least 200% are more preferred.

In general, the acrylic, high refractive index ophthalmic device materials of the present invention preferably contain at least 50% (w/w) of monomer(s) of Formula I. In a more preferred embodiment, the device materials will contain one or more monomers of Formula I in an amount totaling 70% (w/w) or more, and most preferably, 80% (w/w) or more.

Device-forming monomers other than those of Formula I optionally may be included in the materials of the present invention. Many such ophthalmic

device-forming monomers are known. Any known device-forming monomer may be used if it is compatible with the monomer(s) of Formula I present in the ophthalmic device material and does not prevent the ability of the stage 1 polymerization initiator to cure the material such that the material contains no cross-linking or is substantially free of cross-linking. Suitable device-forming monomers other than those of Formula I include, but are not limited to: C₁ - C₈ alkylacrylates, C₁ - C₈ cycloalkylacrylates, N-alkylacrylamides (where alkyl = C₁ - C₄), phenoxyalkylacrylates (where alkyl = C₁ - C₈), and their corresponding methacrylates. Suitable device-forming monomers other than those of Formula I also include N-vinylpyrrolidone. See U.S. Patent No. 5,331,073, the entire contents of which are hereby incorporated by reference, for examples of device-forming materials other than those of Formula 1.

As in the case of the monomer(s) of Formula I, the amount of any other device-forming monomers present in the ophthalmic device materials of the invention will vary depending upon the identity of the monomer(s) of Formula I, the identity of the optional device-forming monomer(s), and the mechanical properties desired for the finished ophthalmic material. In general, for foldable intraocular lens applications, the ophthalmic device materials of the present invention preferably contain about 45% (w/w) or less, and more preferably about 30% (w/w) or less, of device-forming monomers other than those of Formula I.

The ophthalmic device materials also comprise a first stage polymerization initiator selected from the group consisting of low temperature thermal initiators and photoinitiators. Suitable low temperature thermal initiators include azo free-radical initiators, such as 2,2'-azobis(isobutyronitrile) ["AIBN"] and 2,2'-azobis(2,4-dimethylvaleronitrile). Suitable photoinitiators include UV- and blue-light photoinitiators. Many such photoinitiators are known. Preferred blue-light photoinitiators are benzoylphosphine oxide initiators, such as 2,4,6-trimethyl-benzoyldiphenylphosphine oxide; bis-(2,6-dichlorobenzoyl)-4-N-propylphenyl-phosphine oxide; and bis-(2,6-dichlorobenzoyl)-4-N-

butylphenylphosphine oxide. Most preferred is 2,4,6-trimethyl-benzoyldiphenylphosphine oxide, commercially available as Lucirin® TPO from BASF Corporation (Charlotte, North Carolina). See, for example, commonly-assigned, co-pending U.S. Patent Application Serial No. 08/908,229, filed on August 7, 1997, the entire contents of which are hereby incorporated by reference.

The amount of the first stage polymerization initiator in the device materials of the present invention will depend upon the identity of the other ingredients in the materials, the curing conditions, etc. In general, however, the amount of first stage polymerization initiator contained in the mixture to be polymerized in stage of the present invention will be about 3 % (w/w) or less, preferably about 2 % (w/w) or less, and most preferably about 1 % (w/w).

In addition to the device-forming monomer(s) (i.e., monomers of Formula I and any other device forming monomers) and the first stage polymerization initiator, the ophthalmic device materials of the present invention contain a second stage cross-linking agent. The second stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide, substituted dibenzoyl peroxide compounds, and dicumyl peroxide, many of which are commercially available. For example, dicumyl peroxide is available from Hercules Incorporated (Wilmington, Delaware). Suitable substituted dibenzoyl peroxide compounds include 2,4-dichlorodibenzoylperoxide. Dicumyl peroxide is preferred for use with ophthalmic device materials comprising 2-phenylethyl acrylate and 2-phenylethyl methacrylate.

The amount of the second stage cross-linking agent contained in the device materials of the present invention will depend upon, among other factors, the degree of cross-linking desired. In general, however, the amount of second stage cross-linking agent in the ophthalmic device materials will be about 2 - 5 % (w/w), and preferably about 2.5 - 4 % (w/w).

In order to prevent premature cross-linking, the ophthalmic device materials of the present invention do not contain any ingredient having more than one unsaturated bond. Such ingredients include the common cross-linking monomers ethyleneglycol dimethacrylate; diethylene glycol dimethacrylate; ethyleneglycol diacrylate; allyl methacrylates; allyl acrylates; 1,3-propanediol dimethacrylate; 1,6-hexanediol dimethacrylate; 1,4-butanediol dimethacrylate; polyethyleneoxide mono- and diacrylates; and the like.

Ultraviolet absorbing chromophores are optionally included in the ophthalmic device materials of the present invention. Such chromophores prevent or inhibit UV light from damaging the eye. The ultraviolet absorbing chromophore in the device material of the present invention can be any compound which absorbs light having a wavelength shorter than about 400 nm, but does not absorb any substantial amount of visible light, and which is compatible with the device-forming monomer(s) present in the material. The ultraviolet absorbing compound is incorporated into the monomer mixture and is entrapped in the polymer matrix when the monomer mixture is polymerized. Suitable ultraviolet absorbing compounds include substituted benzophenones, such as 2-hydroxybenzophenone, and 2-(2-hydroxyphenyl)-benzotriazoles. It is preferred to use an ultraviolet absorbing compound that is copolymerizable with the device-forming monomers described above so that it will be covalently bound to the polymer matrix. In this way, possible leaching of the ultraviolet absorbing compound out of the device and into the interior of the eye is minimized. Suitable copolymerizable ultraviolet absorbing compounds are the substituted 2-hydroxybenzophenones disclosed in U.S. Patent No. 4,304,895 and the 2-hydroxy-5-acryloxyphenyl-2H-benzotriazoles disclosed in U.S. Patent No. 4,528,311. The most preferred ultraviolet absorbing compound is 2-(3'-methallyl-2'-hydroxy-5'-methyl phenyl) benzotriazole.

If the ophthalmic device material does include a UV-absorber, it is unlikely that a UV polymerization initiator may be used as the first stage polymerization initiator. In such cases, the first stage polymerization initiator

will likely have to be either a low temperature thermal initiator or a blue-light initiator in order to avoid interference with the UV-absorber.

Blue-light absorbing compounds are also optionally included in the device materials of the present invention. If a blue-light absorbing compound, e.g. a yellow dye, is included in the device material of the present invention, then the first stage polymerization initiator will likely not be a blue-light photoinitiator. In the event the device material contains both a UV-absorber and a blue-light absorbing compound, the first stage polymerization initiator will likely be a low temperature thermal initiator. Preferably, blue-light absorbers are copolymerizable with the device-forming monomers. Suitable polymerizable blue-light blocking chromophores include those disclosed in U.S. Patent No. 5,470,932.

The device materials of this invention are prepared by forming a mixture comprising the device-forming monomer(s) (monomer(s) of Formula I and any optional device-forming monomer(s)), the first stage polymerization initiator and the second stage cross-linking agent, along with any UV- or blue-light absorbing compounds and any other suitable ingredients, in the desired proportions. The mixture can then be introduced into a mold of desired shape to form an ophthalmic device. Alternatively, the mixture can be cast in sheets from which the finished form can be obtained by compression molding (generally with mild pre-heating).

In either case (direct cast molding in final form or casting in sheets for subsequent molding), the ophthalmic device material is polymerized in the first stage of the present invention by activating the first stage polymerization initiator (e.g., using heat, UV- or blue-light). In the case where the first stage polymerization initiator is a low temperature thermal initiator and the second stage cross-linking agent is dicumyl peroxide, the thermal initiator may be activated by exposure to temperatures of up to approximately 50 °C or so without activating the dicumyl peroxide. In the case where the second stage cross-

linking agent is a dibenzoyl peroxide or a substituted dibenzoyl peroxide, the curing temperature for stage 1 will generally be about 40 °C or less. The curing parameters, e.g., length of exposure and temperature or intensity of light source, are preferably chosen to accomplish complete polymerization.

5

After the ophthalmic device material is polymerized in stage 1, it is cross-linked in stage 2 of the present invention. Cross-linking is achieved by activating the second stage cross-linking agent using heat. The temperature and length of exposure to heat are determined by the identity and amount of the second stage cross-linking agent and the desired degree of cross-linking to be achieved (i.e., the desired physical properties of the ophthalmic device materials). In general, however, the temperature will be about 90 °C or more where the second stage cross-linking agent is a dibenzoyl peroxide or a substituted dibenzoyl peroxide. In the case where the second stage cross-linking agent is dicumyl peroxide, the activation temperature will be about 125 °C or greater. The duration of heating to achieve the second-stage cross-linking is preferably about four times the half-life of the second stage cross-linking agent at the chosen activation temperature. In the case of dicumyl peroxide and an activation temperature of approximately 135 °C, the duration of heating is approximately 4 hours.

20

The ophthalmic device materials prepared according to the present invention may be used to make almost any type of ophthalmic lens, including contact lenses, intracorneal lenses and intraocular lenses. Ophthalmic lenses constructed of the disclosed materials can be of any design, but are preferably intraocular lenses (IOLs) capable of being rolled or folded and inserted through a relatively small incision. For example, the IOLs can be of what is known as a one piece or multipiece design. Typically, an IOL comprises an optic and at least one haptic. The optic is that portion which serves as the lens and the haptics are attached to the optic and are like arms that hold the optic in its proper place in the eye. The optic and haptic(s) can be of the same or different material. Haptics may be attached to the optic using conventional techniques. In a single piece lens, the optic and the haptics are formed out of one piece of material.

30

Depending on the material, the haptics are then cut, or lathed, out of the material to produce the IOL. In addition to ophthalmic lenses, the materials prepared according to the methods of the present invention may also be used to make other ophthalmic devices including, but not limited to, keratoprotheses and
5 corneal inlays or rings.

Molding and drilling operations are easily carried out if the device, e.g., an IOL optic, is molded between two polypropylene mold halves. The mold containing the cured device material is then placed on a lathe and cut to the
10 desired shape. The mold may then be easily mounted to carry out any drilling operations prior to removing the mold halves. Both the lathing and drilling operations may be facilitated by cooling the mold/device in a freezer to less than 10 °C and preferably less than 0 °C prior to each of these operations. If
15 premature release of one or both mold halves occurs, it may be necessary to use clamps or alternative mold materials or to pretreat the surface of the mold halves.

The invention will be further illustrated by the following examples which are intended to be illustrative, but not limiting.

EXAMPLES

The ophthalmic device materials shown below in Table 1 were prepared as follows:

25 Example 1 was prepared by heating at 70 °C for 7 hours, followed by heating at 100 °C for 7 hours.

Example 2 was prepared by heating at 135 °C for 17.5 hours.

Examples 3 - 14 were prepared using the two-stage method of the present invention. In stage 1, the ingredients were mixed, transferred to 1-mm thick, slab, polypropylene mold, and polymerized by exposure to blue light (Palatray
30 CU/14 mW/cm²) for 15 minutes. In stage 2, the materials remained in the same slab molds and were cross-linked by heating at 135 C for 4, 6 or 10 hours as

indicated.

In all cases (Examples 1 - 14) the ophthalmic device materials were vacuum degassed for approximately 10 minutes immediately prior to filling and sealing
5 the polypropylene slab molds.

The amount of each of the ingredients is expressed in % w/w.

TABLE 1

	1	2	3	4	5	6	7	8	9	10	11	12	13	14
PEA	65	65	65	65	65	60	60	60	55	55	55	50	50	50
PEMA	30	30	30	30	30	35	35	35	40	40	40	45	45	45
OMTP	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
Lucirin TPO	--	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
DiCuP	--	4	4	4	4	4	4	4	4	4	4	4	4	4
BDDA	3.2	--	--	--	--	--	--	--	--	--	--	--	--	--
Perkadox-16	1.8	--	--	--	--	--	--	--	--	--	--	--	--	--
Cure hrs @ 135C	--	17.5	4	6	10	4	6	10	4	6	10	4	6	10
Tg (°C)	--	14.7	0.0	4.3	0.2	5.5	3.8	3.6	6.9	3.5	5.9	6.3	7.9	9.1
% Acetone uptake	--	53.9	60.2	58.3	54.6	59.1	55.9	55.5	61.3	59.0	56.8	62.3	59.7	57.9
% Acetone extractables	--	4.56	4.98	4.96	3.75	4.69	5.04	4.56	6.15	4.66	4.38	6.44	5.50	5.15
Stress (psi)	1200	--	1120	1176	959	1250	1183	1115	1203	1252	1278	1148	1332	1279
% Strain	600	--	1440	1236	965	1215	1156	952	1096	963	872	648	676	654
Modulus, secant (psi)	300	--	227	218	203	391	340	352	572	676	554	1038	1073	1040
Modulus, Young (psi)	--	--	452	410	327	810	760	645	1164	1247	1049	1828	1892	1837

PEA = 2-phenylethylacrylate

PEMA = 2-phenylethylmethacrylate

OMTP = o-Methallyl Tinuvin P (2-(3'-methallyl-2'-hydroxy-5'-methyl phenyl)-benzotriazole)

Lucirin TPO = 2,4,6-trimethyl-benzoyldiphenylphosphine oxide

BDDA = 1,4-butanediol diacrylate

DiCuP = dicumyl peroxide

Perkadox 16 = di-(4-tert-butylcyclohexyl)peroxydicarbonate

The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

10

I CLAIM:

1. A two-stage method for preparing an acrylic, high refractive index ophthalmic device material, wherein the ophthalmic device material comprises

(i) at least one aryl acrylic hydrophobic monomer of the formula



wherein: X is H or CH₃;

m is 0-10;

Y is nothing, O, S, or NR wherein R is H, CH₃, C_nH_{2n+1} (n=1-10) iso OC₃H₇, C₆H₅, or CH₂C₆H₅;

Ar is any aromatic ring which can be unsubstituted or substituted with

CH₃, C₂H₅, n-C₃H₇, iso-C₃H₇, OCH₃, C₆H₁₁, Cl, Br, C₆H₅, or CH₂C₆H₅;

(ii) a first stage polymerization initiator selected from the group consisting of low temperature thermal polymerization initiators and photoinitiators; and

(iii) a second-stage cross-linking agent selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds, and dicumyl peroxide; and

wherein the first stage of the method comprises polymerizing the ophthalmic device material by activating the first stage polymerization initiator without activating the second stage cross-linking agent; and the second stage of the method comprises cross-linking the ophthalmic device material by activating the second stage cross-linking agent.

2. The method of Claim 1 wherein the aryl acrylic hydrophobic monomers is selected from the group consisting of 2-phenoxyethyl acrylate; 2-phenylethylthio acrylate; 2-phenylethylamino acrylate; phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate; 3-phenylpropyl acrylate; 3-phenoxypropyl acrylate; 4-phenylbutyl acrylate; 4-phenoxybutyl acrylate; 4-methylphenyl acrylate; 4-methylbenzyl acrylate; 2-2-methylphenylethyl acrylate; 2-3-methylphenylethyl acrylate; 2-4-methylphenylethyl acrylate; and their corresponding methacrylate

compounds.

3. The method of Claim 1 wherein m is 2-4; Y is nothing or O; and Ar is phenyl.

4. The method of Claim 1 wherein the ophthalmic device material comprises at least two aryl acrylic hydrophobic monomers of Formula (I) and further wherein at least one of the aryl acrylic hydrophobic monomers is a methacrylate monomer and at least one of the aryl acrylic hydrophobic monomers is an acrylate monomer.

5. The method of Claim 4 wherein the ophthalmic device materials comprise a total of at least 50 % (w/w) of aryl acrylic hydrophobic monomers of Formula (I).

6. The method of Claim 5 wherein the ophthalmic device materials comprise a total of at least 70 % (w/w) of aryl acrylic hydrophobic monomers of Formula (I).

7. The method of Claim 1 wherein the ophthalmic device material further comprises one or more monomers selected from the group consisting of C₁ - C₈ alkylacrylates; C₁ - C₈ cycloalkylacrylates; C₁ - C₈ N-alkylacrylamides; C₁ - C₈ phenoxyalkylacrylates; and their corresponding methacrylates.

8. The method of Claim 1 wherein the first stage polymerization initiator is selected from group consisting of 2,2'-azobis(isobutyronitrile); 2,2'-azobis(2,4-dimethylvaleronitrile); UV-photoinitiators; and blue-light photoinitiators.

9. The method of Claim 1 wherein the first stage polymerization initiator is a benzoylphosphine oxide initiators.

10. The method of Claim 1 wherein the amount of the first stage polymerization initiator is about 3 % (w/w) or less.

11. The method of Claim 1 wherein the second stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; 2,4-dichlorodibenzoylperoxide; and dicumyl peroxide.
- 5 12. The method of Claim 11 wherein the second stage cross-linking agent is dicumyl peroxide.
13. The method of Claim 1 wherein the amount of the second stage cross-linking agent is about 2 - 5 % (w/w).
- 10 14. The method of Claim 1 wherein the ophthalmic device material further comprises one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds.
- 15 15. An ophthalmic device material prepared by the method of Claim 1.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/07362

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G02B1/04 C08F20/30 C08F20/36 A61L27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G02B C08F A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 11764 A (ALLERGAN INC) 26 May 1994 (1994-05-26) claims 1-6,10-17,21 page 12, line 1 - line 18 page 14 - page 15; example 1 ---	1
P,A	FR 2 765 583 A (ESSILOR INT) 8 January 1999 (1999-01-08) claim 1 page 8, line 15 - page 9, line 8 ---	1
A	EP 0 308 130 A (IOPTEx RESEARCH INC) 22 March 1989 (1989-03-22) claims 1,5 page 3, line 34 - line 55 page 6, line 15 - line 54 ---	1
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 August 1999

Date of mailing of the international search report

13/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5218 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Depijper, R

INTERNATIONAL SEARCH REPORT

Inter. .onal Application No

PCT/US 99/07362

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 514 096 A (IOPTEX RESEARCH INC) 19 November 1992 (1992-11-19) claims 1,9 page 3, line 29 - line 48 page 5, line 5 - line 57 -----	1
A	EP 0 345 994 A (PILKINGTON VISIONCARE INC) 13 December 1989 (1989-12-13) claim 5 page 3, line 29 - line 47 page 4, line 54 - line 58 page 10, line 13 - line 21 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/07362

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9411764 A	26-05-1994	US 5331073 A	19-07-1994
		AU 5549794 A	08-06-1994
		EP 0667966 A	23-08-1995
		JP 8503506 T	16-04-1996
		US 5359021 A	25-10-1994
FR 2765583 A	08-01-1999	AU 8446098 A	08-02-1999
		EP 0925315 A	30-06-1999
		FR 2765584 A	08-01-1999
		WO 9902574 A	21-01-1999
EP 0308130 A	22-03-1989	US 4834750 A	30-05-1989
		CA 1330474 A	05-07-1994
		CA 1340128 A	17-11-1998
		DE 3870779 A	11-06-1992
		JP 1158949 A	22-06-1989
		US RE36150 E	16-03-1999
EP 0514096 A	19-11-1992	AU 661306 B	20-07-1995
		AU 1617192 A	24-12-1992
		CA 2068446 A	14-11-1992
		JP 5146461 A	15-06-1993
EP 0345994 A	13-12-1989	AT 125827 T	15-08-1995
		CA 1318446 A	25-05-1993
		DE 68923660 D	07-09-1995
		DE 68923660 T	11-04-1996
		ES 2077580 T	01-12-1995
		JP 2140718 A	30-05-1990
		JP 2802287 B	24-09-1998
		US 5505884 A	09-04-1996
		US 5519069 A	21-05-1996
		US 5087392 A	11-02-1992

